๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A program for balancing the allocation of subjects to treatment in a clinical trial

โœ Scribed by Mikel Aickin

Publisher
Elsevier Science
Year
1982
Tongue
English
Weight
357 KB
Volume
15
Category
Article
ISSN
0010-4809

No coin nor oath required. For personal study only.

โœฆ Synopsis

Minimum likelihood allocation (MLA) is a new method for sequentially assigning subjects to treatment groups in a clinical trial. Its aim is to balance the trial, that is, to prevent various treatment groups from containing subjects who have much better or much worse prognoses than the average. The overall strategy of MLA is described, an illustrative example is provided, and the availability of the required computer program is announced.

๐Ÿ“œ SIMILAR VOLUMES

A program to compute power of Fisher tes
A program to compute power of Fisher test at interim point in a clinical trial
โœ R. Wesley; M. Wesley ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› Elsevier Science โš– 453 KB

A method of computing the conditional power of the Fisher exact test for comparing two binomial proportions, given the interim re~tlt~ of a study, is described. A program in BASIC is presented to implement the computation. The program can also be used for computing the power of the test at the begin

A Fortran program for the design and ana
A Fortran program for the design and analysis of sequential clinical trials
โœ John Whitehead; Patrick Marek ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 473 KB

Clinical scientists are becoming increasingly aware of the need to monitor clinical trials in progress, and to validate their procedure by the use of a formal sequential design. An interactive program, written in FORTRAN 77 and called "PEST: Planning and Evaluation of Sequential Tests," is introduce

Modelling Survival Data to Examine Lengt
Modelling Survival Data to Examine Length of Treatment Effectiveness in a Clinical Trial
โœ Prof. Donald J. Slymen ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 592 KB

In some clinical trials where the experimental treatment is found to beeffective in increasing survival, an important question is how long should the patient remain under treatment. Although the trial may not be designed to specifically answer this question, comparisons of the hazard curves among th